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Beryllium: A Chronic Problem
What seest thou else in the dark backward
andabysm oftime?
Shakespeare, The Tempest
Beryllium is the fourth element in the peri-
odic table and the second lightest metal
known. Discovered as an oxide in 1798 by
the French chemist L. N. Vauquelin, berylli-
um was first isolated in 1828, when it was
called "glucinium" owing to the sweet taste
of its salts. Beryllium is the lightest of all
solid, chemically stable substances and has
an unusually high melting point (12870C).
Silver gray and of low density (about one-
third that ofaluminum), with aclose-packed
hexagonal crystalline structure, beryllium
metal has a very high strength-to-weight
ratio. Although it is lighter than aluminum,
it is 40% more rigid than steel. Beryllium
has excellent electrical and thermal conduc-
tiveness but relatively pronounced brittle-
ness, which restricts its applications.
Principal uses of beryllium stem from
the discovery in the 1920s that an addition
additive toglass,ceramic, plastics
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of only 2% beryllium to copper results in
an alloy six times stronger than copper.
beryllium-copper alloys withstand high
temperatures, are extraordinarily hard,
resistant to corrosion, do not spark, and are
nonmagnetic. These alloys are used in
many critical moving parts of aircraft
engines, in key components of precision
instruments, electrical relays, and switches.
Beryllium-copper hammers, wrenches, and
other nonsparking tools are used in the
petroleum industry where sparks from steel
might cause explosions. In the electronics
industry, including personal computers,
Beryllium-copper alloys are found in inte-
grated circuit sockets and electronic con-
nectors. An alloy of 25% beryllium has
some limited use in camera shutters.
Beryllium-copper alloys are also used in
golfclubs, springs, pivots, wheels, pinions,
submarine cable housings, and dental pros-
theses.
Because of its low atomic number,
beryllium is very permeable to X-rays. Its
low neutron absorptance and high scatter-
ing cross-section make it a suitable moder-
ator and reflector in structural materials
within nuclear facilities. Beryllium metal
can be used as structural material in space
technology, in special windows for X-ray
tubes, in gyroscopes, computer parts, and
missle inertial guidance systems, as an
additive in solid propellant rocket fuels,
heat-sink material in high performance air-
craft brakes, mirror components in satellite
optical systems, and development of brass
alloys.
Beryllium shares a number ofchemical
properties with aluminum. Upon exposure
to air or water vapor, a thin film ofberylli-
um oxide forms on its bare metal surface,
rendering it highly resistant to corrosion,
to hot and cold water, and to oxidizing
acids. The ceramic properties of beryllium
oxide make it ideal for production or pro-
tection of materials that are used at high
temperatures in corrosive environments.
Among its special applications are transis-
tor mountings, semiconductor packages,
and microelectronic substrates. Trans-
parency to microwaves allow its use as win-
dows, radomes, and antennae in micro-
wave devices.
Beryllium's aerospace, nuclear energy,
and military applications probably account
for a paucity ofreliable data on its produc-
tion and consumption. Considerable fluc-
tuations in its supply and demand result
largely from variations in government pro-
grams in armaments, nuclear energy, and
aerospace. Compared to available world
production estimates of a dozen nations,
the United States appears to be the largest
producer of beryllium raw materials, with
roughly 4339 tons produced in 1991.
Russia is second, with approximately 1300
tons.
Warnings ofDisease
The dermatological, pulmonary, and sys-
temic toxicity ofberyllium has been recog-
nized only in the past 60 years. Although
reports of beryllium-related lung disease
resulting from inhalation ofthe metal dur-
ing its extraction appeared in European and
Soviet medical journals during the 1930s,
these reports went generally unnoticed or
disregarded in the United States. The role
played by other chemicals, especially fluo-
ride and oxyfluorides, was uncertain.
Gross contamination of equipment,
work areas, and workers' clothing as well
as open and unventilated tanks, alloy fur-
naces, and ore-sulfating ovens were typical
of all three U.S. beryllium processing and
production facilities throughout the 1930s
and 1940s. Accidents and equipment fail-
ure were not uncommon, resulting in even
greater exposures to beryllium oxide and
hydroxide, as well as to beryllium's acid
salts-sulfate, fluoride, and chloride. Skin
contamination with beryllium splinters
was commonplace among metal workers.
From a number ofrooftop stacks less than
40 feet above ground, beryllium effluent
would blowtoward residential areas.
In 1943, the first report was published
in the United States on three cases of
"chemical pneumonia" among Ohio beryl-
lium extraction workers. This report, how-
ever, was overshadowed by NIH Public
Health Service Bulletin No. 181 published
in the same year, which asserted that beryl-
lium was inert toxicologically and that any
toxicity associated with beryllium usage
could be attributed to other constituents
ofits compounds.
In 1946, cases of chronic beryllium
disease (CBD) in the United States were
suspected after instances of sarcoidoses (a
disease characterized by nodules in the
lungs) began occurring among fluorescent
lamp manufacturing workers in Salem,
Massachusetts. Zinc beryllium silicate was
part ofthe phosphors in fluorescent lamps
until 1949. Initially, four cases of Boeck's
sarcoid, a chronic lung disease ofunknown
etiology, attracted attention because they
were reported from a tuberculosis sanitori-
um in women who had worked previously
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in the same department of the same lamp
factory. Thus, an occupational lung disease
seemed more likely than tuberculosis, lead-
ing investigators to report on cases of
"delayed chemical pneumonitis" among 17
more fluorescent lamp workers exposed to
beryllium compounds. Still, doubt existed
as to beryllium's role in the disease. Public
Health Service scientists had failed to
demonstrate toxicity in animals.
By 1947, more cases ofboth acute and
chronic lung diseases were reported from
U.S. Atomic Energy Commisssion labora-
tories as well as from additional lamp fac-
tories. By then, the AEC had become the
major user ofberyllium. By 1945, demand
for beryllium in the United States created
by the atomic bomb development program
was about equivalent to total world
demand up to 1940. A number ofgovern-
ment laboratories had become involved in
beryllium research during and immediately
after World War II. Interest had expanded
tremendously in military as well as civilian
applications ofberyllium.
From 1945 to 1950, when identifica-
tion of beryllium as an occupational and
environmental hazard led to control mea-
sures, acute and chronic beryllium disease
occurred unchecked in the beryllium
extraction, alloy, fluorescent lamp, and
neon sign industries. By 1947, 40 cases of
CBD, including 7 or more deaths, and
about 500 cases of acute disease, with
about 12 deaths, had been reported in the
United States. At least 11 cases of nonoc-
cupational CBD (also known as berylliosis)
had been identified by AEC health and
safety investigators among residents in the
vicinity of the Lorain, Ohio, beryllium
plant. One ofthese deaths from CBD was
a homemaker, whose only exposure to
beryllium occurred from laundering her
husband's work clothes.
Through the auspices ofits Health and
Safety Laboratory located in New York,
the AEC in 1947 began monitoring air-
borne beryllium concentrations and health
hazards in and around the Lorain and
Painseville plants near Cleveland. Merril
Eisenbud, director of the AEC laboratory
at the time, said "Both plants were having
serious health problems, so management
was extremely cooperative. A third plant
near Reading, Pennsylvania, was also hav-
ing a serious problem, but the manage-
ment refused to acknowledge it was due to
beryllium." This position, explains
Eisenbud, was supported by Pennsylvania's
Commissioner ofHealth, who agreed with
the Public Health Service Bureau of
Occupational Health that beryllium was
not toxic. The AEC, he points out, had no
legal basis for its monitoring mission, "and
so the two Ohio plants and the surround-
ing communities became our field labs.
Gross contamination. A beryllium sulfating mill in 1936 provided little protection forworkers.
Information from the Pennsylvania plant
was incorporated when it became avail-
able."
Acute Disease
Although few quantitative data exist on
exposure to beryllium before 1947, data
gathered by the International Agency for
Research on Cancer between 1947 and
1948 leave little doubt that extremely high
concentrations were encountered in the
workplace. In U.S. beryllium extraction
facilities, concentrations greater than 1000
micrograms per cubic meter (pg/m3) were
not uncommon. Exposures measured late
in 1946 using the filter-paper dust sampler
method ranged from 110 to 4710 pg/m3
in an extraction plant's furnace area.
Concentrations of590-43,300 pg/m3 were
monitored by AEC investigators in the
Lorain, Ohio, plant in 1947-48.
Prevalence estimates ofacute beryllium
disease in workers ranged as high as 7% in
the early literature. Caused mainly by dusts
or fumes ofsoluble beryllium salts released
during the extraction ofberyllium hydrox-
ide and production ofberyllium oxide and
metallic beryllium, two types of acute
beryllium disease have been described clin-
ically; their progression is either rapid or
slow. A "fulminating" or rapid type devel-
ops within 72 hours of massive exposure,
while an "insidious" version develops sev-
eral days or weeks after exposure to lower
concentrations of beryllium salts or low
fired oxide. Common clinical signs include
shortness ofbreath on exertion; a nonpro-
ductive, often paroxysmal, cough; chest
pain; acrocyanosis (persistent discoloration
offingers, hands, toes, and feet, accompa-
nied by cold and sweaty fingers and toes);
sibilant rales over the lung bases (asthma-
like hissing sound); and a sudden, marked
drop in vital capacity. Rapid heart rate,
weight loss, and anorexia might also occur.
Death occurs in 10% of the cases, nearly
all the fulminant type. Those with insidi-
ous-onset acute disease typically recover in
one to three months, but in some cases
recovery may take as long as six months
and there's a risk oflonger-lasting respira-
tory problems. Approximately 17% of
workers with acute disease subsequently
develop CBD.
In 1949, Eisenbud and his AEC associ-
ates recommended occupational and com-
munity ambient air standards for beryllium
that remain intact today, adopted by
OSHA. For occupational air exposures, a
permissible level of 2.0 pg/m3 was estab-
lished based on an 8-hour time-weighted
average. A 30-minute maximum peak level
was set at 25 pg/m3. Beryllium concentra-
tions in air surrounding the factories is not
to exceed 0.01 pg/m3. The latter air stan-
dard became the first ambient air quality
standard in the United States, and it pre-
ceded all others byabout 25 years.
Subsequent studies on the epidemiolo-
gy ofberyllium disease revealed these stan-
dards were effective in eliminating most
acute lung disease. The U.S. Beryllium
Case Registry (BCR), established in
Massachusetts in 1952 and now main-
tained by NIOSH in Cincinnati, collects
data on the epidemiology, diagnosis, clini-
cal features, course, and complications of
beryllium-related diseases, including cases
of acute beryllium-related pneumonitis
and chronic beryllium-related nonmalig-
nant lung disease. Individuals referred to
the BCR for evaluation ofberyllium-relat-
ed diseases were employed in a variety of
occupations, but most have worked in
beryllium extraction and smelting, metal
production, and fluorescent tube produc-
tion.
The BCRhas admitted only 15 cases of
acute disease since 1950. Some individuals
may have developed a less severe, subacute
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form of the chemical pneumonitis
due to beryllium exposure and
were misdiagnosed as having aviral
or other pulmonary infection. The
potential for acute disease due to
accidental exposure to high con-
centrations remains despite im-
provements in workplace ventilato-
rycontrols.
In 1983, Eisenbud, who became
director of New York University's
Institute of Environmental Med-
icine, and co-authorJudith Lisson, a
NIOSH epidemiologist, reviewed
the BCR's 224 acute and 622 chron-
ic cases, which include 65 CBD
cases attributed to ambient airpollu-
tion in the vicinity of beryllium
plants or to dust brought home on
workclothes. An additional 45 CBD
cases, along with a dozen acute
reports not included in the BCR,
were also examined. The authors
observed a "striking reduction" in
the number of CBD cases among
workers first exposed after the
1950s, with no case reported for an
individual first exposed after 1972.
According to Eisenbud and Lisson,
exposure control methods adopted
in the 1950s accounted for these
reductions despite a marked increase
in the use ofberyllium. However, in Pebbles
light of more recent research and product.
dinical developments, the impact of
beryllium control standards on the incidence
ofCBD is much less certain.
Misdassifications and Populations
at Risk
It is generally agreed that the epidemiology
of CBD has been limited by misclassifica-
tion ofthe disease and ofexposure status in
the BCR. Until 1970, entry into the BCR
was based on two criteria: significant expo-
sure to beryllium and evidence of chronic
lower respiratory tract disease. Chronic
beryllium disease was initially confused
with sarcoidosis, from which it was clini-
cally indistinguishable before the advent of
current immunologic tests. Some cases of
CBD may have been excluded from the
BCR, and some cases of sarcoidosis may
have been erroneously included. Thus,
limited conclusions can be drawn from
published studies in the 1950s and 1960s
regarding the prevalence of beryllium dis-
ease. Estimates ofCBD prevalence in most
series range from about 2 to 5%.
The size of the population at risk is
unknown, with estimates ofthe number of
U.S. workers exposed ranging from 30,000
to 800,000, which includes more than 20
industries and trades in which there is
potential exposure to beryllium. Sum-
marizing data on occupational exposure to
and Bam-Barn. Beryllium nuggets are melted down for
:sincluding nuclear reactors.
beryllium for the period 1 June 1979 to 31
January 1984, based on inspections of
workplaces, OSHA found levels in excess
of2 pg/m3, mainly in the traditional beryl-
lium industry, but also in high-technology
industries (semiconductor, precision elec-
tronics, spacecraft, and missile manufac-
ture industries).
CBD Reconsidered
In its early stages, CBD may be complete-
ly asymptomatic, as observed in apparent-
ly healthy individuals with lung X-ray
abnormalities. In other cases, CBD may
begin with nonspecific respiratory symp-
toms, including mild shortness of breath
and cough, but no recognizable changes
on chest films. Gradually, the majority of
patients develop symptoms more charac-
teristic ofchronic disease: cough, burning
chest pain, progressive shortness ofbreath
(dyspnea) with exertion, weakness,
fatigue, dyspnea at rest, and, characteristic
ofadvanced disease, anorexia, weight loss,
acrocyanosis, and clubbing of finger and
toe bones. Signs ofright heart failure and
cor pulmonale (enlargement and strain of
the right side ofthe heart due to increased
pressure in the pulmonary artery from
lung damage) may also be detected in
advanced cases.
CBD's clinical course is ex-
_ tremely variable. Some individuals
a remain stable for many years, oth-
__ ers progress more precipitously,
developing severe respiratory
symptoms within a few months.
The majority experience a slow,
inexorable decline in pulmonary
function. Mortality from CBD
occurs in an estimated one-third of
cases.
"Most clinicians are taught that
beryllium disease is a dinosaur,"
states Lee S. Newman of the
Occupational and Environmental
Medicine Division, National
Jewish Center for Immunology
and Respiratory Medicine, in
Denver. "But the chronic form of
the disease is far from extinct. In
fact, with increasing usage ofberyl-
lium in industry, the absolute
number ofcases can be expected to
increase as well."
Newman points out that even
with careful ventilatory controls
and monitoring, CBD continues
to occur because it is due to a
hypersensitivity to beryllium, in
which an antigen-specific immune
response plays a central role in
pathogenesis. Exposed individuals
use in become sensitized to beryllium and
accumulate pathologic clusters of
cells called granulomas around
beryllium particles in the walls ofalveoli.
"Such hypersensitivity can develop in
some individuals following even low-level
exposures well within permissible expo-
sure limits," Newman explains.
Indeed, the original theory that CBD
was a delayed chemical pneumonitis due to
direct toxicity was problematic. Beryllium
levels in tissue did not correlate with the
presence of CBD, nor did disease inci-
dence correlate with exposure history; the
majority ofworkers with high exposures
never developed disease, while some with
seemingly low or minor exposures devel-
oped severe disease, as did others whose
duration ofexposurewas relativelybrief.
As early as 1951, Eisenbud and others
proposed that CBD was immunologically
mediated, a proposition that became more
valid that same year when skin-patch test-
ingwith beryllium salts demonstrated that
beryllium could be sensitizing. In 1959,
biopsies of patch test sites after 6 weeks
demonstrated the presence of epithelioid
cell granulomas, further evidence ofa cell-
mediated immunologic response. More
recently, laser microprobe mass spectrom-
etry has identified beryllium in these
lesions.
In vitro lymphocyte proliferation test-
ing has been applied since the 1980s to
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individuals sensitive to beryllium prolif-
erate extensively. Blood cells drawn
peripherally, or lung cells retrieved via
intranasal insertion of a bronchoscope
into the lung, are cultured in the pres-
ence of beryllium salts. Using a radiola-
beled DNA precursor such as thymidine,
a determination of the cells' level of
radioactivity provides an index of prolif-
eration. Studies show proliferation test-
ing is a specific and sensitive indicator of
the cell-mediated immune response to
beryllium. The less invasive peripheral
blood test allows screening for beryllium
sensitization and early CBD among
beryllium-exposed workers and offers a
reliable method for differentiating CBD
from sarcoidosis. However, no consensus
exists on whether the patch test or prolif-
eration test is the best for CBD diagnosis
or surveillance screening.
Newman and his Denver colleagues
have used blood proliferation testing in
epidemiologic studies ofberyllium work-
ers in Colorado at the Rocky Flats
nuclear weapons plant and at a beryllium
ceramics company. They've noted that
about 2% ofall beryllium-exposed work-
ers who have volunteered for testing are
either sensitized to beryllium or have evi-
dence of CBD. A DOE screening pro-
gram for all current and former Rocky
Flats workers, now in its second year, is
confirming that percentage.
"Some people who haven't been
exposed in over 30 years now have beryl-
lium disease, with symptoms manifested
very recently. So it seems latency has a
range from a few months up to 30 or
more years," said Newman. "We don't
truly know the latency for either berylli-
um sensitization or beryllium disease.
We don't actually know how long it
takes from the time you're exposed to the
time you first become sensitized, nor do
we know the length oftime it takes from
sensitization to development of granulo-
mas or other lung function reactions to
beryllium. Despite what is in the litera-
Lee S. Newman-The chronic form of beryllium dise
extinct.
ture, we truly don't know."
According to Newman,
about half of those who are
simply sensitized without dis-
ease will develop pulmonary
granulomas, most doing so
within three to four years of
sensitivity testing. Another
subset ofindividuals followed
for six years has not devel-
oped any sign of disease nor
developed lung granulomas.
"It's possible that some who
become sensitive to beryllium Carl Shy-
may never develop the dis- excess lung maye .developgthdis- cates a link ease. Only a longitudinal sure anddise
study will answer that ques-
tion," said Newman.
"There's a wide spectrum of severity
and rate of disease progression,"
Newman continues. "It's becoming clear
that CBD is a disease that results from at
least two hits: there may be an element
of individual genetic risk and the ele-
ment ofexposure."
In terms of exposure, Newman
believes that the Rocky Flats and berylli-
um ceramics company studies contain
findings that suggest a challenge to the
"old immunologic dogma of no
dose-response relationship in CBD."
While several CBD cases were associated
with trivial or unrecognized beryllium
exposure (a secretary, a security guard at
Rocky Flats; a sweeper with the ceramics
company), there were also CBD rates
higher than 2% in both workplaces-
15.8 percent in some jobs-among work
groups with presumed greater beryllium
exposure: beryllium machinists, workers
with sawing tasks, metallurgical opera-
tors, chemical control operators, berylli-
um dry pressers, and those involved in
beryllium process development/engineer-
ing.
For Newman, the implications are
clear: further control of the amount of
exposure and kind ofexposure will lower
beryllium disease rates. "So there is a
place for improved industrial hygiene
_ and primary prevention
_s here," he said. Moreover,
Ca in terms ofsecondary pre-
T_ vention, Newman recom-
mends broad-based med-
ical surveillance with the
beryllium lymphocyte
-5 proliferation test in all
h beryllium-using indus-
/f /1 -God tries, in conjunction with
chest X-rays, to identify
Jj sensitivity and subclinical
disease among former and
current workers. Those
ease is far from identified as such should
be enrolled in research fol-
-A
cc
bet
easE
low-up for defining a prog-
0 nosis and in clinical inter-
vention trials. As to a con-
z sensus on frequency of sur-
.> veillance, that too remains
to be reached.
'The Cancer Connection
Four IARC working groups
(1972, 1980, 1987, 1993)
have carefully sifted through
and interpreted animal and
epidemiologic data on beryl-
pattern of lium's potential as a human
rncers indi-* anweesindi- carcinogen. The first group expo- considered the four epi- e. demiogical studies available
at that time to be inadequate to evaluate
the human carcinogenic effects of berylli-
um. In the 1980 evaluation, IARC con-
cluded that beryllium and its compounds
are carcinogenic in rats, rabbits, and mon-
keys. IARC also concluded that lung
tumors had been produced in rats and
monkeys by inhalation or intratracheal
exposure to many beryllium metals, sul-
fates, and alloys.
The 1980 IARC working group also
reviewed four epidemologic cohort studies
and concluded that the evidence for an
increased risk for lung cancer from occu-
pational exposure to beryllium was limit-
ed. No new study was available at the
time of the third review; however, on the
basis of evidence of carcinogenicity of
some beryllium compounds on the above
three species ofanimals, IARC stated that
beryllium should be considered a suspect
carcinogen to humans.
A 1991 study of workers enrolled in
the BCR by NIOSH epidemiologists Kyle
Steenland and Elizabeth Ward, found an
excess risk of lung cancer two times
greater than normal, which was most pro-
nounced among workers with acute dis-
ease.
In a 1992 evaluation of the mortality
experience of workers exposed to berylli-
um, Ward and her NIOSH associates
reported results ofa cohort study of9225
male workers employed by two companies
at seven beryllium plants in Ohio and
Pennsylvania. A total of280 cancers were
observed, versus 221.5 expected based on
U.S. rates. In this study, however, the
population was not drawn from the BCR
but from personnel records matched
against records of individuals from the
Social Security Administration. These
were obtained from the study plants for
all quarters from 1940 through 1967.
Vital status ofall workers in the study was
determined as of31 December 1988 from
the Social Security Administration, IRS,
post office cards mailed to the last address,
Veteran's Administration records, the
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Health Care Financing Administration,
and the National Death Index. Death cer-
tificates were obtained from state vital sta-
tistics offices.
Significant excess mortality rates for
lung cancer were observed from two of
the oldest plants located in Lorain, Ohio,
and Reading, Pennsylvania. Lung cancer
mortality rates did not increase with
longer duration of employment, but did
increase with longer latency (time since
first exposure). Lung cancer was particu-
larly elevated among workers at the
Lorain plant with a history ofacute beryl-
lium disease. However, this lung cancer
excess was not restricted to plants operat-
ing in the 1940s. Elevated rates were also
observed for four of the five study plants
that operated in the 1950s for workers
hired during that decade.
Decade of hire was one of the
strongest correlates oflung cancer mortal-
ity in the total cohort. The IARC work-
ing group noted that, given the much
higher exposures to beryllium before
1950, and the fact that 73% ofthe cohort
worked for less than five years, duration
ofemployment did not separate that seg-
ment ofthe cohort that received the high-
est exposures to beryllium.
In their summation ofthe human car-
cinogenicity data, the IARC working
group said it was satisfied that cigarette
smoking was not a confounding factor
and that it did not appear to explain the
increased lung cancer risk. However, the
group did point to aspects of the 1991
and 1992 studies that would limit the
interpretation that occupa-
tional exposure to beryllium
compounds is the "most plau-
sible explanation" of the
increased lung cancer risk
observed. These included
absence of any individual
measurements ofexposures to
beryllium, relatively low
excess risk for lung cancer,
and absence of any mention
of exposure of workers to
other lung carcinogens in the
workplace (although the AnthstiynMf
working group stated it saw sensationhe
no evidence that other car- verybroad c
cinogens were present). Still,
upon scrutinizing the experi-
mental and epidemiological evidence,
IARC decided there was sufficient evi-
dence for both animal and human car-
cinogenicity ofberyllium.
Commenting on the relatively small
excesses of lung cancer deaths observed,
Carl Shy, professor of epidemiology at
the University of North Carolina, and a
member of the fourth IARC Working
Group, says, "We have to look at the
o
wo
asti
har
whole pattern, the consistency ofthe evi-
dence, to say there's likely to be a rela-
tionship between exposure and disease. If
it were a chance relationship, you
wouldn't expect to find a pattern of
excess as has been demonstrated here."
In the face ofthe IARC decision, con-
troversy continues. The beryllium indus-
try contends that the oncogenicity of
beryllium compounds has not been
unequivocally established and that envi-
ronmental exposure controls in the work-
place reduce whatever risk may exist to
negligible levels. Industry scientific advis-
ers have also put forth the possibility that
inhalation exposure to acid mists result-
ing from the sulfate ore extraction process
may account for excess lung cancer
observed in the NIOSH studies.
According to Ward and Steenland, how-
ever, such exposure would usually be
accompanied by an increase in laryngeal
cancer, which hasn't been demonstrated
in beryllium studies. They say a paucity
ofmonitoring information makes it diffi-
cult to determine ifthe acid mist levels at
plants using ore sulfating were high or
low and how widespread they were with-
in these plants. (Apart from the Lorain
plant where the highest excess of lung
cancer was found, a sulfating process was
also used at three plants that began oper-
ating after the 1950s.) In any event, the
beryllium industry must comply with
OSHA's Hazard Communication
Regulation that warning labels and mate-
rial safety data sheets to employees and
customers must state that beryllium is a
human carcinogen. In addi-
tion, NIOSH must notify
o current and former beryllium
industry employees that they
may have been exposed to
cancer-causing substances in
the workplace.
An upcoming conference
on beryllium-related diseases
co-sponsored by NIEHS,
DOE, OSHA, and NIOSH is
scheduled. Meanwhile, gener-
icchi-The al agreement seems to exist
)rker corm- on both sides of the cancer
otake on a argument that the issue of
acter. CBD is of far greater magni-
tude and significance. Indeed,
it may well be that any future
OSHA proposals to lower current occu-
pational beryllium exposure standards
would be determined more by concerns
over CBD than cancer. Peter Infante,
who directs the Office of Standards
Review at OSHA, says he believes there
will be more cases ofCBD than lung can-
cer from low-dose beryllium exposures.
"The issue, in my opinion now, is how
are we going to prevent these people from
getting chronic beryllium disease? Cases
are being recognized at very low expo-
sures. That's the challenge."
A Genetic Test for Beryllium
Disease
The advent ofa genetic screening test for
CBD is viewed by some individuals asso-
ciated with the beryllium industry like
the proverbial light at the end ofthe tun-
nel, a way to eventually eradicate CBD
from the workplace. Martin Powers, for-
mer vice president of Brush-Wellman,
Inc. (the world's largest beryllium proces-
sor and producer), and now executive
director of BISAC, the Beryllium
Industry Scientific Advisory Committee,
says "For years we've been searching for
this, trying to find people who were sus-
ceptible so we could, in effect, protect
them or take them out ofthe industry. If
we could take that small percentage and
screen them out, we could eliminate dis-
ease, eliminate the marketing problem
that comes with having a toxic material,
and we could begin doing away with
some of those very expensive control
measures." Genetic screening, however,
raises ethical concerns about workplace
discrimination such as who will make
these decisions and how such decisions
will affect a worker's ability to obtain
health insurance or other employment.
Last October in Science, researchers
from Italian universities in Rome and
Modena, partially supported by a grant
from BISAC, described for the first time
a genetic marker for CBD. The authors,
Luca Richeldi, Rosa Sorrentino, and
Cesare Saltini, presented evidence that a
small difference in the genetic sequence
in the major histocompatibility complex
(MHC) allele, HLA-DPB1, identifies
people at increased risk of developing
CBD if exposed to beryllium. They
observed that 32 of 33 occupationally
exposed workers with CBD exhibit the
amino acid glutamate in a potentially
critical location (position 69) in a cell-
surface glycoprotein of MHC HLA-
DPB1, which may participate in antigen
recognition. Of a control group of 44
beryllium-exposed workers without
CBD, 70% did not have glutamate in
this position.
Because lymphocyte proliferation tests
neither predict beryllium disease nor its
risk, Richeldi and his co-authors see a
possible role for the genetic marker in
association with lymphocyte testing to
identify and follow-up persons at risk for
beryllium disease. Newman concurs. He
says the addition of a genetic marker
would allow employers to potentially
reduce beryllium exposure for high-risk
individuals and more effectively target
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monitoring and early disease
detection.
Commenting on their
findings, however, Newman
states we have a lot to learn
about the interaction be-
tween exposure to beryllium
and inheritance ofthe mark-
er. He also states that it's
premature to advocate that
employers deny or discour-
age employment ofworkers Martin Power
with genetic risk of CBD. susceptible pi
Social and ethical issues need the beryllium
consideration. And given intelligentand
that almost all people in the
study with CBD have the marker, while
manywithout CBD also have the marker,
only a population-based investigation can
answer the questions that are necessary
for designing a genetic screening test:
What proportion of employees with the
marker will develop the disease, and what
proportion of workers with the marker
will not? "Even ifmost CBD patients test
positive for the marker, it may not be
helpful to identify up to 30% of the
potential workforce as at risk ifthe preva-
lence of CBD among beryllium-exposed
workers is only two to five percent," said
Newman.
Chronic beryllium disease may even-
tually have the distinction of becoming
the first model for assessing the value of
genetic testing in preventing occupational
disease. However, the possibility ofgenet-
ic screening in the workplace is already
raising concerns that go beyond science.
Current screening programs for beryllium
sensitization and disease have created
issues surrounding worker compensation
for occupational disability and insurance.
Because there is currently no way to accu-
rately predict the natural course ofCBD,
questions have been raised about whether
former or current workers who've been
defined as having subclinical disease
would qualify for occupational disability,
compensation for health care costs, and
lost income.
"I think the whole question of com-
pensation has to take on a very broad
character," says Anthony Mazzocchi of
the Oil, Chemical and Atomic Workers
Union. "There's a responsibility on the
part of government and employers for
continuing medical surveillance and
treatment ofworkers, and to follow this
population for life."
For some, the concerns take on major
societal implications if genetic testing is
used for pre-employment worker selec-
tion. Sheldon W. Samuels, executive vice
rs-
soF
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ser
president of The Workplace Health
Fund, says the purpose of the interna-
tional beryllium industry's sup-
a port of a genetic testing re-
search program "is to defend
what they have already pro-
claimed oxymoronically as the
discovery of the 'first occupa-
tional genetic disease'. One
overt purpose of the research,
as stated before witnesses, is to
establish a case for the exclu-
sion of purportedly defective
workers from employment on
-Keeping the basis of a genetic differ-
Ale out of ence."
dustry is Samuels sees this as a har-
isible. binger ofan eventual caste sys-
tem created by industry and
warns that genetic screening, like any
other kind ofscreening, has the potential
for unjust application and shortsighted
social policy. "Marketplace corporate
policies could create a caste of suscepti-
bles, ofsociallydefined lepers," he said.
According to Samuels, given comput-
erization and existing international
records linkage, woefully inadequate pro-
visions for protecting worker confiden-
tiality, poorly regulated informed con-
sent, and the ease ofimplementing wide-
spread testing, a specter has been raised of
a bleak tomorrow, one in which many
thousands ofworkers would be tagged for
life, and their offspring tagged as well, as
insurance, employment, and perhaps even
mating risks. Says Samuels: "Industrial
genetic screening should only take place
in a society that has created a system of
screening within neutral community
structures that economically and socially
protect the individual and family before,
during, and after avoluntary, confidential
counseling process. It must not take place
in the coercive milieu of the typical
industrial setting."
Powers says he is not persuaded by
the social argument and is astounded by
objections to screening people. "The
worker is entitled to a clean workplace.
The employer should provide it. But the
facts are that the beryllium industry
hasn't been able to do it completely.
Keeping susceptible people out is intelli-
gent and sensible. The beryllium industry
is one industry where a good faith effort
has been made even before it was legally
required to get exposures down to a safe
level. But we're still getting [CBD] cases
in the plants. The beryllium employer
cannot guarantee a safe workplace. It
seems almost criminal to give people the
right to go in there and get sick if they
want to."
Yet Samuels envisions another reason
behind the industry's interest in a molec-
ular biological research program. The
program may be used to successfully mar-
shall data for use against all claims for
compensation on health care costs and
income replacement, and against calls for
more stringent environmental protection.
Samuels says the laws of most states
archaically assume a "single cause in
cases ofworkers' compensation for occu-
pational disease. Thus, reasons Samuels,
the hypothesis ofCBD being caused by a
defective worker, rather than a defective
workplace, would be an economically
appealing defense for an industry no
longer protected by government, as it
once was during the nuclear arms race,
and which must now confront the recent
IARC classification of beryllium as a
human carcinogen. This classification,
which may carry more weight in Europe
than in the United States, might have
implications for continued use ofberylli-
um-copper alloy in certain industries
where it can be replaced.
Few would doubt that improved
industrial hygiene standards for beryllium
have prevented many cases of beryllium
disease. But total compliance with a peak
standard is difficult in this industry;
equipment malfunctions, accidents, start-
up problems, and new employee inexperi-
ence can all contribute to significant devi-
ations beyond allowable air concentra-
tions. It seems that disease is likely to
occur even when current exposure stan-
dards are maintained, yet it remains
unknown whether more stringent allow-
able exposure levels would prevent sensi-
tization, chronic beryllium disease, or
cancer.
Leslie Lang
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North Carolina.
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